Durect corp's nash trial on schedule to be completed in first half of 2020

Durect announces completion of enrollment in its phase 2a clinical trial of dur-928 in psoriasis and 50% enrollment in its phase 1b dur-928 clinical trial in nash.durect corp - company expects to announce top line data from psoriasis trial by end of this year.durect corp - nash trial is on schedule to be completed in h1 2020 & co plans to announce top line study results following completion of trial.
DRRX Ratings Summary
DRRX Quant Ranking